New drug trial targets Hard-to-Treat cancers after standard options fail
NCT ID NCT03667170
Summary
This study is testing an experimental immunotherapy drug called KN035 for people with advanced solid tumors that have specific genetic markers (dMMR or MSI-H). The trial is for patients whose cancer has continued to grow despite receiving standard treatments. Researchers want to see if KN035 can help control the cancer by boosting the body's immune system to fight it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University Cancer Hospital, Peking University
RECRUITINGBeijing, Beijing Municipality, 100010, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.